Menu
Back to User profile » Professor Zhong-Yu Yuan
Papers published by Professor Zhong-Yu Yuan:
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial
Chen Y, Li WX, Wu JH, Chen GH, Yang CM, Lu H, Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Hong RX, Jiang KK, Zhong YY, Zhang G, Tienchaiananda P, Oikawa M, Yuan ZY, Chen QJ
Breast Cancer: Targets and Therapy 2024, 16:223-231
Published Date: 12 April 2024
Multifunctional Graphene Oxide Nanodelivery Platform for Breast Cancer Treatment
Mo Y, Liu W, Liu P, Liu Q, Yuan Z, Wang Q, Yuan D, Chen XJ, Chen T
International Journal of Nanomedicine 2022, 17:6413-6425
Published Date: 15 December 2022
Levistilide a Induces Ferroptosis by Activating the Nrf2/HO-1 Signaling Pathway in Breast Cancer Cells
Jing S, Lu Y, Zhang J, Ren Y, Mo Y, Liu D, Duan L, Yuan Z, Wang C, Wang Q
Drug Design, Development and Therapy 2022, 16:2981-2993
Published Date: 7 September 2022
Novel Signatures Based on the Lymphocyte-to-C-Reactive Protein Ratio Predict the Prognosis of Patients with Early Breast Cancer: A Retrospective Study
Wang L, Zhang YL, Jiang C, Duan FF, Yuan ZY, Huang JJ, Bi XW
Journal of Inflammation Research 2022, 15:3957-3974
Published Date: 13 July 2022
A Novel Inflammatory-Nutritional Prognostic Scoring System for Patients with Early-Stage Breast Cancer
Hua X, Duan F, Zhai W, Song C, Jiang C, Wang L, Huang J, Lin H, Yuan Z
Journal of Inflammation Research 2022, 15:381-394
Published Date: 16 January 2022
An Aging-Related Gene Signature-Based Model for Risk Stratification and Prognosis Prediction in Breast Cancer
Yuan J, Duan F, Zhai W, Song C, Wang L, Xia W, Hua X, Yuan Z, Bi X, Huang J
International Journal of Women's Health 2021, 13:1053-1064
Published Date: 3 November 2021
Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
Duan F, Song C, Ma Y, Jiang K, Xu F, Bi X, Huang J, Hong R, Huang Z, Lu Q, Yuan Z, Wang S, Xia W
Drug Design, Development and Therapy 2021, 15:3463-3473
Published Date: 10 August 2021
Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis
Zhang K, Hong R, Xu F, Xia W, Kaping L, Qin G, Zheng Q, Lu Q, Shi YX, Yuan ZY, Wang SS
Cancer Management and Research 2018, 10:2573-2580
Published Date: 14 August 2018
HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
Qin T, Yuan Z, Peng R, Bai B, Shi Y, Teng X, Liu D, Wang S
OncoTargets and Therapy 2013, 6:341-347
Published Date: 9 April 2013